Navigation Links
Bruker Announces Acquisition of Nanoindenting Leader Hysitron
Date:1/24/2017

BILLERICA, Mass., Jan. 24, 2017 /PRNewswire/ -- Bruker today announced that it has acquired Hysitron, Inc., a technology leader in the development, manufacture, and sale of nanomechanical test instrumentation. The acquisition adds Hysitron's innovative nanomechanical testing instruments to Bruker's existing portfolio of atomic force microscopes (AFMs), surface profilometers, and tribology and mechanical testing systems, significantly enhancing Bruker's leadership position in nanomaterials research markets. Hysitron's 2016 revenues were approximately $20 million. Financial details of the transaction were not disclosed.

Headquartered in Eden Prairie, Minnesota, privately-held Hysitron® has pioneered solutions to measure mechanical properties of materials at the nanoscale since 1992. Its industry-leading nanoindentation products are used by premier academic and industrial researchers and engineers in materials science, the life sciences, and semiconductor applications. In addition to nanoindentation and microindentation, Hysitron's instrument capabilities include tribology, modulus mapping, dynamic mechanical analysis, and in-situ SEM (scanning electron) and TEM (transmission electron) nanomechanical testing.

"Hysitron has been recognized as the global market and technology leader in the field of nanomechanical property measurements for quite some time," said Mark R. Munch, Ph.D., President of the Bruker NANO Group. "As a leader in atomic force microscopy instrumentation, we plan to realize a number of valuable application synergies by adding Hysitron's instruments to our Bruker NANO Group nanoscale surface and materials characterization product portfolio. In addition, Hysitron's products are quite complementary to our macroscale mechanical and tribology test instruments, providing the most complete range of testing capabilities to the market."

"We have built a strong reputation at Hysitron for truly top-level instrumentation that pushes the limits of nanoindenting technology, but have been looking to leverage the strengths of a larger global organization to help bring these capabilities to their full potential," added Thomas Wyrobek, CEO and Co-Founder of Hysitron, Inc. "With Bruker's great commitment to research and their long history of academic collaboration, we are excited about the ways they can provide the global infrastructure and processes that we have always wanted, while maintaining intense focus on developing the best possible solutions to enable our customers' success."

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect. Our actual future performance may differ materially from such expectations as a result of important risk factors, which include, in addition to those identified in our Annual Report on Form 10-K for the year ended December 31, 2015 and our other subsequent filings with the Securities and Exchange Commission, risks and uncertainties associated with our ability to finalize and close, and then manage and integrate the acquisition of Hysitron, Inc. These risks and uncertainties could cause actual results to differ materially from those stated or implied in these forward-looking statements. We expressly disclaim any obligation to update or revise these forward-looking statements, except as required by law or regulation.

About Hysitron, Inc.
Hysitron is the world leader in the development and commercialization of nanomechanical test instruments and has designed, manufactured, and serviced cutting-edge technology for the scientific community since 1992. As the pioneer of in-situ imaging with nanomechanical property measurement capabilities, Hysitron has grown with the nanotechnology market for over two decades.

About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Investor Contact:
Miroslava Minkova
Bruker Head of Investor Relations
T: +1 (978) 663-3660 x1479
E: miroslava.minkova@bruker.com

Media Contact:
Stephen Hopkins
Bruker Nano Surfaces MarCom Supervisor
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-nanoindenting-leader-hysitron-300395228.html


'/>"/>
SOURCE Bruker Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon
2. Bruker Announces Acquisition of CMO InVivo Biotech to Expand Molecular Biology, Microbiology and Pathology Consumables and Assay Business
3. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
4. Annual Conference about Technology Solutions for People with Disabilities Announces Program
5. Probiotic Action Announces Probiotics Lead the Digestive Health Market
6. Verenium Announces Preliminary Financial Results For Fiscal 2012
7. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
8. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
9. EAG Announces New General Manager of Release-To-Production (RTP) Division
10. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
11. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):